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Abstract 
Background: The leading cause of death among the obese population is heart failure and stroke prompted by struc‑
tural and functional changes in the heart. The molecular mechanisms that underlie obesity‑related cardiac remod‑
eling are complex, and include hemodynamic and metabolic alterations that ultimately affect the functionality of the 
myocardium. G protein‑coupled receptor kinase 2 (GRK2) is an ubiquitous kinase able to desensitize the active form of 
several G protein‑coupled receptors (GPCR) and is known to play an important role in cardiac GPCR modulation. GRK2 
has also been recently identified as a negative modulator of insulin signaling and systemic insulin resistance.
Methods: We investigated the effects elicited by GRK2 downregulation in obesity‑related cardiac remodeling. For 
this aim, we used  9 month‑old wild type (WT) and GRK2+/− mice, which display circa 50% lower levels of this 
kinase, fed with either a standard or a high fat diet (HFD) for 30 weeks. In these mice we studied different parameters 
related to cardiac growth and lipid accumulation.
Results: We find that GRK2+/− mice are protected from obesity‑promoted cardiac and cardiomyocyte hypertrophy 
and fibrosis. Moreover, the marked intracellular lipid accumulation caused by a HFD in the heart is not observed in 
these mice. Interestingly, HFD significantly increases cardiac GRK2 levels in WT but not in GRK2+/− mice, suggesting 
that the beneficial phenotype observed in hemizygous animals correlates with the maintenance of GRK2 levels below 
a pathological threshold. Low GRK2 protein levels are able to keep the PKA/CREB pathway active and to prevent HFD‑
induced downregulation of key fatty acid metabolism modulators such as Peroxisome proliferator‑activated recep‑
tor gamma co‑activators (PGC1), thus preserving the expression of cardioprotective proteins such as mitochondrial 
fusion markers mitofusin MFN1 and OPA1.
Conclusions: Our data further define the cellular processes and molecular mechanisms by which GRK2 down‑reg‑
ulation is cardioprotective during diet‑induced obesity, reinforcing the protective effect of maintaining low levels of 
GRK2 under nutritional stress, and showing a role for this kinase in obesity‑induced cardiac remodeling and steatosis.
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Background
Obesity is a complex condition that affects virtually 
all age and socioeconomic groups and threatens to 
overwhelm both developed and developing countries. 
The growing incidence of obesity is particularly preoc-
cupying given its strong association with cardiovascular 
disease and overall mortality. Although obesity is most 
commonly caused by a disruption in energy homeostasis 
due to the imbalance between dietary energy consump-
tion (calorie-dense food and drinks) relative to energy 
expenditure (energy loss via metabolic and physical 
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activity), the etiology of obesity is highly complex and 
includes several factors that promote an increase in body 
fat mass [1].
Besides an altered metabolic profile, a variety of adapta-
tions/alterations in cardiac structure and function occur 
in the individual as adipose tissue and lipids accumulate 
in excessive amounts, even in the absence of comor-
bidities such as type 2 diabetes or hypertension [2]. For 
instance, the mass of the left ventricle has been shown to 
grow and correlate proportionally with body weight [3]. 
Eventually, prolonged persistence of obesity causes both 
left ventricular systolic and diastolic dysfunctions [4]. In 
humans, increased cardiac mass has been postulated to 
result from epicardial fat deposition and fatty infiltra-
tion of the myocardium [5]. In fact, triglyceride content 
in human cardiac tissue is increased in obese compared 
with normal-weight subjects [6]. Accumulation of intra-
myocellular triglycerides in the heart is also a commonly 
described feature of most animal models of obesity [7, 8]. 
The ectopic presence of triglycerides and lipid metabo-
lites such as ceramides has been related to lipotoxicity 
and cardiomyocyte apoptosis [9]. Interestingly, a palmitic 
acid-ceramide pathway accounts for impaired insulin 
sensitivity [10], whereas ceramide inhibition has been 
suggested to be an effective deterrent to heart disease 
risk in conditions like hyperinsulinemia [11]. In fact, a 
positive correlation between cardiac lipid accumulation 
and cardiac dysfunction has been established giving rise 
to the term lipotoxic cardiomyopathy.
Another common feature of the obese heart is impaired 
insulin signaling. It starts to develop within 2  weeks of 
high fat diet (HFD) in animal models, and represents an 
early adaptation of the heart to caloric excess that pro-
motes the development of diabetic cardiomyopathy [12, 
13]. Interestingly, intra-myocellular lipid content appears 
to better predict muscle insulin resistance than fat mass 
in lean individuals and non-obese, non-diabetic but insu-
lin-resistant adults and children (see references in [14]). 
This condition not only alters cardiac metabolism, but 
also increases myocardial oxygen consumption, reduces 
cardiac efficiency by uncoupling of the mitochondria and 
increases oxidative stress [15].
G protein-coupled receptor kinase 2 (GRK2) is a ser-
ine/threonine kinase originally discovered to regulate G 
protein-coupled receptor (GPCR) desensitization and 
known to play an important role in cardiac function 
and dysfunction [16, 17]. GRK2 expression increases in 
different cardiac hypertrophy and heart failure human 
conditions [16, 17]. Interestingly, GRK2 is emerging as 
an important signaling hub with a complex interactome 
and has recently been identified as a direct modulator of 
insulin signaling in several tissues, including the heart 
[18, 19]. Interestingly, GRK2+/− mice (expressing some 
50% less protein than control littermates) show improved 
systemic insulin sensitivity in different insulin resistance 
models [19, 20], and accordingly, inducible GRK2 down-
modulation reverts key features associated to the diabetic 
phenotype in HFD-fed mice [21]. On the other hand, we 
have recently described that GRK2 levels are increased in 
the hearts of adult ob/ob mice as well as in mice fed with 
a HFD for 12 weeks [19].
Given the emerging role of GRK2 as a regulatory hub 
in heart metabolism and physiology, we have explored 
the role of GRK2 dosage in the development of obesity-
induced cardiac remodeling and steatosis in 9 month-old 
mice, since obesity-related cardiac pathological events 
become more prevalent during adulthood. Our results 
show that decreased GRK2 protein levels is per se able 
to prevent intra-myocellular lipid accumulation, cardiac 
steatosis, fibrosis and hypertrophy promoted by the long-
term HFD feeding, by mechanisms involving increased 
expression of markers of mitochondrial fusion (such as 
MFN1 and L-OPA1/S-OPA1 ratio) and fatty acid oxida-
tion regulation (such as PGC1) downstream of the PKA/
CREB cascade.
Methods
Animals
Experiments were performed on male wild type (WT) 
and hemizygous-GRK2 (GRK2+/−) mice maintained 
on the C57BL/6 background. The animals were bred and 
housed on a 12-h light/dark cycle with free access to food 
and water. GRK2+/− mice and their corresponding WT 
littermates were fed ad  libitum either an standard diet 
(SD, providing 13% of total calories as fat, 67% as car-
bohydrate and 20% as protein; 2014S Rodent Mainte-
nance Diet, Teklad, Harlan, Barcelona, Spain) or a high 
fat diet (HFD, providing 45% of total calories as fat, 35% 
as carbohydrate and 20% as protein, Rodent Diet D12451, 
Research Diets, New Brunswick, NJ, USA) for 30 weeks. 
Animals were maintained at a room temperature of 
22 ± 2 °C with a relative humidity of 50 ± 10% and under 
pathogen-free conditions. Body weight and food intake 
were measured weekly.
Metabolic assays
Insulin tolerance tests (ITT) were performed as previ-
ously described [22]. Animals were fasted for 4  h, and 
baseline blood samples were collected from the tail. Insu-
lin (0.8 U/kg body weight) was administered by i.p. injec-
tion, and blood samples were taken 15, 30 and 60  min 
after injection. Glucose concentration (mg/dl) was deter-
mined using an automatic analyzer (One Touch Ultra), 
from Life Scan.
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Heart collection and processing
Mice were euthanized using CO2 and weighted. Hearts 
were surgically removed, washed, dried and immedi-
ately weighted. Auricles were removed and ventricles 
were sliced transversally in four portions. The two central 
slices were fixed in 4% paraformaldehyde and embedded 
in paraffin or Tissue-Tek® OCT for histological analysis. 
The other two portions were frozen in liquid nitrogen for 
protein and gene expression analysis.
Cardiomyocyte hypertrophy determination
Paraffin blocks of heart slices were cut in 6  μm-thick 
slices and stained with Masson’s trichrome for the eval-
uation of cardiomyocyte area. Digital images of trans-
versally cut cardiomyocytes were captured using a light 
microscope (Olympus, Germany) at 20× magnification. 
Four mice were employed for each condition (three fields 
per heart), and cardiomyocyte size was calculated by 
quantitation of 150–200 cells per field using image analy-
sis software (ImageJ).
Fibrosis staining and quantitation
Fibrosis was quantified in Picro-sirius red-stained sec-
tions in order to detect collagen fibers. The area of 
interstitial fibrosis was identified, after excluding the 
vessel area from the region of interest, as the ratio of 
interstitial fibrosis or collagen deposition to total tis-
sue area and expressed as %CVF (collagen volume frac-
tion). For each heart, 10–15 fields were analyzed with 
a 40× objective lens under transmitted light micros-
copy (Leica DM 2000; Leica AG, Germany). All meas-
urements were performed blind in an automated image 
analysis system (Leica LAS,4.3; Leica AG, Germany). 
Images were calibrated with known standards. A single 
researcher unaware of the experimental groups per-
formed the analysis.
Gene expression analysis
mRNA from heart tissue of at least six mice per condi-
tion was isolated as described in [19]. RT-PCRs were 
performed by the Genomic Facility at Centro de Bio-
logia Molecular “Severo Ochoa” (CBMSO, Madrid), 
using Light Cycler equipment (Roche, Indianapolis, IN, 
USA). Gene expression quantifications were performed 
using both commercial Taqman Gene Expression Assay 
probes (Applied Biosystems, Life Technologies, Grand 
Island, NY, USA) and self-designed probes purchased 
from Sigma labeled with Syber Green (see Additional 
file 1: Table S1). qPCRs and statistical analysis of the data 
were performed by the Genomic Facility using GenEx 
software. A geometric mean of two stably expressed and 
commonly used reference genes (hprt and rps29) was 
used for data normalization.
Western Blot analysis
Heart tissue was homogenized as described in [19]. Typi-
cally 40 μg of total cardiac protein was resolved per lane 
by SDS-PAGE and transferred to a nitrocellulose mem-
brane. Blots were probed with specific antibodies against 
GRK2 (sc-562), PKA (sc-903), GAPDH (sc-32233) and 
nucleolin (sc-13057) from Santa Cruz Biotechnology, 
Dallas, TX, USA; CREB (9198), P-CREB (Ser 133) (9198), 
AMPK (2532), P-AMPK (Thr 172) (2535) and P-PKA 
(Thr 197) (4781) from Cell Signalling Technology, Dan-
vers, MA, USA; MFN1 (ab57602) from Abcam, Cam-
bridge, UK; and OPA1 (612606) from BD Transduction 
Laboratories San Jose, CA, USA.
Intracellular lipid droplet quantification
OCT frozen blocks of heart tissue were cut in 6 μm-thick 
slices, mounted on 10% glycerol in PBS-DAPI (5  ng/μl) 
to visualize the nucleus, and stained with Oil red O as 
described [23]. All sections were examined using a fluo-
rescence resonance energy transfer (FRET) equipment 
coupled to an inverted Axiovert200 (Zeiss, Germany) 
microscope in the Confocal Microscopy Facility of our 
center. Oil red O-stained sections were examined in 
epifluorescence using a DsRed (500–650 nm) and DAPI 
(359–371 nm) excitation filter. Digital images of arbitrary 
fields were captured at 100× magnification from three 
different hearts (ten fields per mouse). Total lipid drop-
let content per total cell area and droplet areas within 
each field were determined using image analysis software 
(ImageJ).
Statistical analysis
All data are expressed as mean values ±SEM and N rep-
resents the number of animals. Statistical significance 
was analyzed using unpaired two-tail Student’s t test 
except when repeated measures were taken over time 
in the same group of animals when a two-way ANOVA 
followed by Bonferroni’s post hoc test was used. All data 
were analyzed using GraphPad Prism software. Dif-
ferences were considered statistically significant when 
P < 0.05.
Results
Decreased levels of GRK2 attenuates the diet‑induced 
obesity phenotype
Two months after birth mice were fed either a SD or HFD 
for 30  weeks. While both genotypes significantly gained 
weight after HFD feeding compared with SD-fed mice (see 
Additional file 1: Figure S1), GRK2+/− mice maintained 
a significantly leaner phenotype compared with WT ani-
mals (Fig. 1a; Additional file 1: Figure S1), in the absence of 
differences in food intake (Fig. 1b). Since systemic insulin 
resistance is a common comorbidity in obese individuals, 
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we performed insulin tolerance tests (ITTs) on animals of 
each genotype. We observed that 9-month old GRK2+/− 
mice were more sensitive to insulin than their WT litter-
mates in SD conditions (Fig.  1c), in line with previously 
published results [20]. Interestingly, such enhanced insu-
lin sensitivity detected upon GRK2 downregulation was 
even more pronounced after a long-term HFD feeding 
(Fig. 1d) as reflected by analysis of the area under the curve 
(Fig.  1e). These results build on previous data from our 
laboratory that showed improved maintenance of body 
weight and insulin sensitivity in GRK2+/− mice after a 
12-week HFD, indicating that these animals are able to 
preserve these features even after 30 weeks of HFD feeding 
when they are already 9 months old.
Lower levels of GRK2 protect hearts from high fat 
diet‑induced hypertrophy and fibrosis
In order to determine if obesity-induced cardiac remod-
eling could be affected by GRK2 dosage we set out to 
study the hearts of mice fed for 30 weeks with HFD, since 
12 weeks were not enough to induce cardiac hypertrophy 
(data not shown). We first observed that HFD feeding pro-
voked cardiomegaly in WT animals while, in GRK2+/− 
mice, heart dimensions were indistinguishable from those 
of SD-fed mice (Fig. 2a). Interestingly, a similar effect was 
also observed at a cellular level where a reduction of GRK2 
prevented the increase in cell size that was induced by 
HFD in WT mice (Fig. 2b), even considering that hemizy-
gous animals display a mild, non-pathological cardiomyo-
cyte hypertrophy in SD conditions (in agreement with 
previous reports [19]). The degree of fibrosis as measured 
by Picro-sirus red staining after 30 weeks of HFD feeding 
in WT mice doubled that found in SD-fed control animals, 
while this pathological increase in fibrosis was also absent 
in HFD-fed GRK2+/− mice (Fig. 2c).
In order to further characterize the cardiac hypertro-
phy that we detected, we quantified the mRNA expression 
levels (Fig.  2d) of α-skeletal actin (Acta1), a prototypical 
Fig. 1 GRK2+/− animals show an attenuated obese and insulin‑resistant phenotype after long‑term HFD feeding. a Comparison of body weight 
evolution and body weight gain (the former analyzed by two‑way ANOVA followed by Bonferroni post hoc test) between WT and GRK2+/− ani‑
mals after 30 weeks of HFD feeding. b Daily food intake (statistical analysis: two‑tailed unpaired T test). c, d Intraperitoneal insulin tolerance tests 
(ITT) in SD‑ and HFD‑fed mice (statistical analysis: two‑way ANOVA), and e histogram showing the product of ITTs area under the curve (AUC). Data 
in all panels are mean ± SEM with N = 6–7 per genotype and condition using unpaired two‑tail Student’s t test analysis except where indicated. 
*P < 0.05, **P < 0.01, ***P < 0.001
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marker of cardiac hypertrophy, B-type natriuretic pep-
tide (BNP), a highly sensitive marker of cardiac pathol-
ogy/stress, and sarco/endoplasmic reticulum Ca2+ 
ATPase (Serca2), a marker of cardiac functionality that is 
decreased in most cases of hypertrophied failing hearts. 
The gene expression profile for Acta1 precisely correlates 
with the degree of cardiomyocyte hypertrophy observed. 
GRK2+/− mice did not show the pathological increase 
in BNP expression observed in WT littermates after the 
HFD. We found no significant changes in Serca2 expression 
in either genotype or feeding regime, but there is a ten-
dency towards an increased expression of Serca2 in SD-fed 
GRK2+/− mice compared to SD-fed WT animals. This 
would indicate a possible amelioration of cardiac func-
tionality upon GRK2 downregulation in this model, in line 
with previously reported results in other models of cardiac 
hypertrophy [19, 24]. In sum, we can conclude that low lev-
els of GRK2 prevent the development of obesity-induced 
cardiomyocyte and heart pathological hypertrophy, and 
also of cardiac fibrosis after a long-term HFD feeding.
Fig. 2 Low levels of GRK2 protect mice from long‑term (30 weeks) HFD‑induced heart hypertrophy and fibrosis. a Heart weight to tibial length 
ratio in HFD‑fed 9 month‑old WT and GRK2+/− mice, compared with their littermates fed with standard diet (N = 6–9 per genotype and condi‑
tion). b Cardiomyocyte cross‑sectional area from each genotype expressed in μm2 (N = 4). c The ratio of interstitial fibrosis or collagen deposition 
to the total tissue area was measured in Picro‑sirius red‑stained sections and expressed as %CVF (collagen volume fraction) (N = 4–7 animals per 
genotype and condition). Results are from 10 to 15 photomicrographs from each heart (magnification ×40). d Expression of markers of cardiac 
hypertrophy (Acta1), cardiac stress (BNP) and cardiac functionality (Serca2) were quantified by qPCR and normalized by a geometrical mean of HPRT 
and RPS29 (N = 5–6). Data are mean ± SEM with a two‑tail unpaired Student’s t test statistical analysis.*P < 0.01, ***P < 0.001
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GRK2+/− mice are protected from HFD‑promoted 
intramyocardial lipid accumulation
One of the characteristic pathological features of hearts 
from obese individuals is the accumulation of lipid drop-
lets in the cardiac cell that can promote lipotoxicity. 
Staining of fat depots with Oil red O (Fig.  3a) showed 
that the amount of intracellular lipid droplets was sig-
nificantly lower in either HFD- or SD-fed GRK2+/− 
mice hearts than in their littermate WT counterparts. 
The amount of intracellular fat remained unchanged 
in GRK2+/− mice regardless of the type of diet used, 
whereas it increased in WT cardiac tissue after HFD 
feeding (Fig. 3b). Interestingly, the mean size of intracel-
lular lipid depots was significantly larger in cardiomyo-
cytes of HFD-fed WT animals compared to any other 
condition (Fig. 3c). These differences in cardiac fat depots 
or in the size of intramyocellular lipids could not be 
ascribed to changes in the levels of free fatty acids in the 
plasma of these animals that were not statistically differ-
ent in GRK2+/− mice compared to WT (see Additional 
Fig. 3 Intracellular lipid accumulation in the heart is enhanced in WT compared with GRK2+/− littermates after standard or long‑term HFD feed‑
ing. a Frozen heart sections were stained with Oil red O and DAPI to visualize and quantify intracellular lipid droplets and nuclei, respectively. Lipid 
droplets in each condition are shown in black and white after image processing. Results are from at least ten photomicrographs from each heart 
(magnification ×100). b Percentage of the area occupied by lipid droplets in cardiomyocytes for each condition. c Lipid droplets areas were classi‑
fied according to their sizes as medium (0.5–1 μm2) or large (>1 μm2). The total area of lipid droplets of each size was normalized with the total area 
of lipid droplets. Statistical analysis was performed using unpaired two‑tail Student’s t test. Data are mean ± SEM (N = 3). *P < 0.05, **P < 0.01
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file 1: Figure S2). Of note, the levels of plasma NEFA in 
WT animals were slightly but significantly reduced after 
this HFD what does not happen in GRK2+/− mice. This 
could be ascribed to a deterioration of lipolysis in the 
WAT of WT mice caused by this long term diet. Con-
sistent with this notion, a preserved lipolytic response 
of adipocytes to fasting and to β agonists after GRK2 
downregulation has been described [21, 25]. Overall, 
our results suggest that GRK2 downregulation maintains 
cardiac lipid storage at bay and prevents the pathological 
accumulation of intramyocellular lipids even in the face 
of a long-term HFD feeding.
HFD‑dependent increase in GRK2 protein levels correlate 
with the development of hypertrophy and cardiac 
steatosis
In consistency with previous results showing that GRK2 
levels were increased upon feeding young animals a HFD 
for 12  weeks [19], we found that a 30-week long HFD 
also induced an increase in cardiac GRK2 protein lev-
els, but this increase was only significant in WT mice. 
GRK2+/− animals maintained significantly lower levels 
of GRK2 even after the long term HFD feeding (Fig. 4a) 
that remained comparable to those of SD aged-matched 
controls. We detected no significant changes in GRK2 
mRNA after HFD feeding (Fig.  4b) what suggests that 
the observed increase in cardiac GRK2 protein levels 
probably responds to post-translational regulatory mech-
anisms in agreement with what was previously described 
[26, 27]. In sum, these data indicate that GRK2 protein 
levels increase in cardiac tissue in parallel with HFD-
induced hypertrophy and steatosis, and that this increase 
is not detected in GRK2 hemizygous animals.
GRK2 downregulation keeps the PKA/CREB and AMPK 
pathways active and promotes higher levels of PGC1 
and mitochondrial fusion markers
In order to explore a possible mechanism by which lower 
GRK2 levels could help prevent intramyocellular lipid 
accumulation in cardiac tissue, we focused on the fam-
ily of peroxisome proliferator-activated receptor γ-PPAR 
γ-coactivator proteins (PGC1). These factors induce the 
transcription of mitochondrial genes involved in oxida-
tive phosphorylation and fatty acid oxidation, and also 
of genes governing mitochondrial fusion such as mito-
fusins (MFN) and optic atrophy 1 (OPA1) [28]. In agree-
ment with what is described for other models of cardiac 
hypertrophy [28], we observed a tendency towards a 
decrease in PGC1α/β and in PPARα mRNAs caused by 
HFD in WT mice. This downregulation is not detected 
in GRK2+/− hearts where the mRNA levels of these 
genes are not reduced but instead significantly increased 
upon HFD feeding (Fig.  5a). No changes in established 
markers of mitochondrial biogenesis such as TFAM or 
Fig. 4 GRK2 protein levels increase in the hearts of long‑term HFD‑fed animals. a GRK2 protein levels in cardiac tissue normalized by GAPDH levels 
are expressed as fold‑increase over SD‑fed WT animals (N = 3–4 mice per genotype and condition). A representative blot is shown. The arrow indi‑
cates the band corresponding to GRK2 (as determined in the last lane using 0.5 ng of recombinant purified protein) and the asterisk an unspecific 
band. b mRNA levels of GRK2 were quantified by pPCR and normalized by a geometrical mean of HPRT and RPS29 (N = 5–6). Data are mean ± SEM 
and statistical analysis performed by two‑tail unpaired Student’s t test.*P < 0.05, **P < 0.01
Page 8 of 13Lucas et al. Cardiovasc Diabetol  (2016) 15:155 
in mitochondrial-encoded mRNAs such as COI were 
detected in these samples (Additional file  1: Figure S3). 
Since PPARα cooperates with PGC1 proteins in the 
upregulation of genes involved in fatty acid import and 
β-oxidation in the mitochondria, these data could indicate 
that a β-oxidative transcriptional profile would remain 
active in GRK2+/− hearts after a 30-week HFD in the 
absence of apparent changes in mitochondrial biogenesis.
Several mechanisms are known to promote PGC1 
mRNA accumulation. Activation of PKA and consequent 
phosphorylation of CREB is among the more impor-
tant ones [28]. A role for up-regulated GRK2 leading to 
impaired catecholamine responsiveness has been shown 
in various animal models of cardiac disease including 
cardiac hypertrophy, whereas inhibiting GRK2 func-
tion enhances signaling downstream of beta-adrenergic 
receptors (βAR) and leads to improved catecholamine 
sensitivity [24]. Thus, we set out to explore the status 
of the PKA/CREB cascade in the hearts of these mice. 
As depicted in Fig.  5b, we can observe a two to three-
fold increase in the activatory phosphorylation of PKA 
in Thr197 [29] in GRK2+/− compared to WT HFD-
fed mice. This activation of PKA is accompanied by 
increased phospho-Ser133-CREB, a readout of phos-
phorylation by PKA that is required for CREB activation 
[30]. This result shows that the PKA/CREB cascade is 
more active in GRK2+/− than in WT mice after a long-
term HFD and provides an explanation for the increased 
Fig. 5 GRK2 downregulation keeps active the PKA/CREB and AMPK pathways and promotes higher levels of PGC1 and mitochondrial fusion mark‑
ers in cardiac tissue after long‑lasting HFD‑feeding. a Expression of the PPARγ coactivator 1‑alpha (ppargc1α), beta (ppargc1β) and of PPARα were 
quantified by qPCR and normalized by a geometrical mean of HPRT and RPS29 (N = 5–6 animals per genotype and condition). b Densitometric 
analysis and representative blots of total and phospho‑PKA (Thr197); total and phospho‑CREB (Ser133) and total and phospho‑AMPK (Thr172) in WT 
and GRK2+/− mice after 30 weeks of HFD (N = 5–6). c MFN1 and OPA1 protein levels were analyzed in cardiac tissue of the same animals. Graphs 
display the MFN1 data normalized by Nucleolin levels or the calculated L‑OPA1 vs S‑OPA1 ratio (N = 5–7). Data are mean ± SEM and are expressed 
as fold‑change over wild type HFD conditions. Statistical analysis was performed by two‑tail unpaired Student’s t test. *P < 0.05, **P < 0.01, 
***P < 0.001
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levels of PGC1α/β mRNA detected in these animals. 
Besides PKA, other upstream proteins can phosphoryl-
ate CREB on Ser133, including AMPK [31]. Moreover, 
PGC1α is also a known target of AMPK. In this regard, 
we also observe an increased phosphorylation of AMPK 
in the hearts of GRK2+/− compared to WT mice after a 
long-term HFD (Fig. 5b), what may provide an additional 
mechanism for the increased levels of PGC1α/β mRNA 
detected in these animals.
Finally, with the aim to determine whether the upregu-
lation of PGC1α/β results in the control of downstream 
targets, we analyzed the levels of proteins related to mito-
chondrial fusion known to be induced at least in part by 
PGC1 transactivation [28]. As shown in Fig. 5c, the pro-
tein levels of mitofusin MFN1, a well-established acti-
vator of mitochondrial fusion, are significantly larger in 
the hearts of GRK2+/− animals after a HFD compared 
to WT mice. Also, the ratio of L-OPA with respect to 
S-OPA, a known marker of mitochondrial fusion events 
that correlates with preserved cardiac function [32], is 
slightly but significantly increased in HFD-fed GRK2+/− 
mice compared to their WT counterparts. These results 
may suggest that mitochondrial fusion and, therefore, 
mitochondrial function could remain more active in the 
hearts of GRK2 hemizygous mice in the context of a long 
term HFD feeding.
Discussion
Reduced GRK2 protein levels preserve insulin sensitivity 
after a long‑term HFD in adult mice
In this work we present evidence that unmasks a pro-
tective role of low GRK2 levels on the effects of obe-
sity-induced cardiac remodeling. We find that adult 
GRK2+/− mice gain less weight after a long period 
(30  weeks) of HFD feeding building on our own data 
describing similar effects after a 12  weeks-long HFD-
induced obesity [19, 20], and also when GRK2 was 
depleted in the middle of the HFD period [21]. Of note, 
the animals used in this work have reached adulthood 
(9  months-old at sacrifice), a differential characteris-
tic compared to most studies where rodents initiate the 
HFD shortly after weaning, and are analyzed when they 
are still young (typically 4–5  months old). We believe 
this experimental approach could more reliably mimic 
the current profile of human obesity whose incidence in 
middle-age adults is higher than in younger cohorts, as 
is the presence of associated comorbidities such as car-
diovascular disease [33]. Interestingly, insulin sensitivity 
in GRK2+/− mice is preserved after a HFD compared to 
WT littermates, indicating that a lower GRK2 dosage is 
able to protect animals against the development of diet-
induced insulin resistance even in adult mice and after 
long-lasting HFD-induced obesity.
Obesity‑induced pathological cardiac remodeling is 
prevented by low levels of GRK2
We also report here that GRK2+/− animals appear to be 
protected from pathological cardiac remodeling induced 
by obesity. Hemizygous GRK2 mice display neither cardio-
megaly nor cardiomyocyte hypertrophy or fibrosis after a 
HFD of 30 weeks while these alterations are present in con-
trol WT mice. Obesity is characterized by an inappropri-
ate expansion and dysfunction of the adipose tissue, and 
this excessive adiposity provokes structural and functional 
changes in the heart through hemodynamic (volume over-
load) and non-hemodynamic factors such as inflammation, 
hyperglycemia and insulin resistance, altered adipokine 
secretion, ectopic lipid deposition and lipotoxicity [34]. 
Since decreased levels of GRK2 attenuate the overall obese 
phenotype, we cannot discard that the protection against 
obesity-induced cardiac remodeling observed in GRK2+/− 
mice could be promoted, at least in part, by the effect 
of GRK2 downregulation in other tissues. For instance, 
decreasing levels of GRK2 was shown to improve white 
adipose tissue lipolysis [21] and increase the thermogenic 
capacity of brown adipose tissue [25] thus providing effects 
independent of a specific role of GRK2 in the heart that can 
affect cardiac steatosis. However, GRK2 downmodulation 
has been described to be beneficial in other types of cardiac 
hypertrophy, such as after thoracic aortic constriction, in 
genetically-based mice models of cardiac dysfunction and 
after myocardial infarction [35–37], whereas high GRK2 
levels correlate well with the degree of heart hypertrophy 
in different human and murine conditions [16, 37, 38]. So, 
since the molecular mechanisms underlying cardiomyocyte 
cell growth in response to different pathological stimuli 
appear to have common features [39], we believe there are 
grounds to speculate that cardiac GRK2 could be playing a 
direct role in modulating obesity-induced heart hypertro-
phy and cardiac remodeling.
Consistent with this notion, we report an increase in 
cardiac GRK2 levels in WT HFD-fed mice that corre-
lates with enhanced cardiac hypertrophy and remod-
eling. Notably, the HFD-induced increase in cardiac 
GRK2 levels appears to be an early event in the develop-
ment of obesity-induced cardiac alterations, since it is 
detected after 12 weeks on HFD in WT animals [19]. At 
this point insulin resistance is present, not only systemi-
cally [20], but also in the heart as determined after acute 
intravenous insulin injection [19], but no hypertrophy is 
yet detected in terms of heart weight/tibial length ratio. 
A similar phenotype has been reported using genetic 
animal models of obesity (db/db and ob/ob) in which 
insulin resistance settles at the early onset of the obese 
phenotype (5–10  weeks after weaning) while left ven-
tricular hypertrophy is only apparent much later [40, 
41]. The precise molecular mechanism underlying the 
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HFD-promoted increase in cardiac GRK2 levels remain 
to be established, although, in the absence of mRNA 
changes, it is tempting to suggest that insulin resistance 
may trigger mechanisms modulating protein stability or 
degradation such as those already described to control 
the level of this kinase in other tissues and cells [26, 27].
Low GRK2 helps preserve a cardiac transcriptional profile 
compatible with lipid catabolism in the face of a long‑term 
HFD
A key feature of HFD-induced cardiac remodeling is lipid 
accumulation in the myocardium that has been reported 
to correlate with the degree of obesity [42]. Inappropri-
ate triglyceride deposition into cytoplasmic lipid droplets 
enlarges the intracellular pool of fatty acyl-CoA thereby 
providing substrate for oxidative and non-oxidative (e.g. 
ceramide synthesis [10, 11]) metabolic pathways lead-
ing to oxidative stress, cellular dysfunction and apopto-
sis and insulin resistance [43]. However, such packaging 
of lipid excess into lipid droplets can also be regarded as 
an adaptive response of the tissue to accommodate an 
excessive energy supply while keeping low concentra-
tions of lipotoxic intermediates [44]. We have observed 
that the amount of lipid droplets is larger in WT than in 
GRK2+/− mice either after SD or HFD, so GRK2+/− 
hearts seem to be protected against this ectopic lipid 
accumulation. In addition, the mean size of intracellu-
lar lipid droplets was also smaller in cardiomyocytes of 
HFD-fed GRK2+/− mice than in WT littermates. Along 
this line, in skeletal muscle it has been proposed that the 
reduced lipid droplet size may coincide with increased 
oxidative enzymatic capacity [45]. Given the already men-
tioned role of GRK2 in fatty acid handling in white and 
brown adipose tissues [21, 25], it is tempting to suggest 
a similar direct effect of GRK2 downregulation in other 
organs such as the heart, where fatty acid oxidation is the 
main source of ATP. Notably, GRK2 inhibition has been 
shown to decrease lipid load in FASN transgenic mice 
[46]. In fact, both basal respiratory rate (oxygen consump-
tion rate) and ATP-linked respiration, parameters that 
measure ATP production, were significantly increased 
when GRK2 was inhibited in mouse cardiomyocytes. 
Moreover, elevated GRK2 levels negatively regulated 
myocyte β-oxidation and FA-mediated oxygen consump-
tion when mouse cardiomyocytes were fed with palmitate 
[47]. Taken together, these data stimulate further research 
to evaluate whether these novel roles of GRK2 in the reg-
ulation of lipid handling in the heart are also relevant in 
obese patients and if lowering GRK2 is able to preserve 
cardiac metabolism in the face of dietary lipid excess.
In this regard, the PGC family of coactivators plays a 
pivotal role in the control of cardiac mitochondrial num-
ber and function by regulating transcription of fatty acid 
oxidation and mitochondrial fusion-related genes. Accord-
ingly, downregulation of PGC1 is a major mechanism 
in the transition of the oxidative metabolism to a more 
pathological glycolysis-dependent one observed in hyper-
trophied hearts and late-stage heart failure [32]. PGC1α 
is downregulated in numerous rodent models of car-
diac hypertrophy or dysfunction (see references in [28]). 
We also detect a repression of PGC1α/β and of PPARα 
mRNA after HFD-driven cardiac hypertrophy in WT ani-
mals whereas this tendency is not only spared but, rather, 
inverted in GRK2+/− mice. In our model, PGC1 proteins 
seem to be primarily acting via binding to PPARα to acti-
vate lipid import and catabolism transcription and not via 
other transcription factors linked to the activation of mito-
chondrial biogenesis, although this particular conclusion 
merits further investigation in future studies. In GRK2+/− 
animals, the maintenance of PGC1α/β mRNA levels could 
be explained by the elevated activation that we detect of 
the upstream PKA/CREB route, possibly as a result of 
the decreased desensitization and enhanced signaling of 
βAR and other Gs-coupled GPCR that would be expected 
in the heart of GRK2+/− mice [24]. Interestingly, GRK2 
hemizygous animals also show an increased activation of 
AMPK, an activator of mitochondrial fatty acid oxidation 
and of PGC-1α expression [45], also suggested to play a 
protective role in heart failure [48]. Thus, it is tempting to 
speculate that GRK2 downregulation may enhance AMPK 
stimulation downstream of several GPCR known to acti-
vate cardiac AMPK and to be modulated by GRK2, such 
as alpha-adrenergic, vasopressin (reviewed in [48]) or 
adiponectin receptors [46, 49]. An increased activation of 
AMPK signaling pathway in BAT and WAT of GRK2+/− 
mice upon cold exposure has also been reported [25].
We also find a preservation of PGC1-dependent MFN1 
and OPA1 expression upon long-term HFD feeding in 
GRK2 hemizygous mice. These mitochondrial fusion 
markers appear downregulated in animal models of car-
diac hypertrophy and in cardiac tissue sections from 
diabetic patients who concomitantly show increased 
mitochondrial fragmentation and impaired mitochon-
drial function [50]. Since these markers are upregulated 
in GRK2+/− hearts, it is tempting to suggest that these 
animals could present a conserved mitochondrial fusion 
capacity what is compatible with the improved mito-
chondrial respiration towards fatty acids described in 
murine cardiomyocytes upon GRK2 inhibition [47].
Conclusions
Taking these data together, we could envisage a model 
(Fig. 6) in which a HFD would directly or indirectly pro-
voke an increase in cardiac GRK2 levels in parallel with 
(or as a cause or consequence of ) heart hypertrophy, 
fibrosis and steatosis. This alteration in GRK2 dosage 
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would subsequently affect GPCR signaling pathways, 
such as β-adrenergic, thus contributing to further disturb 
heart physiology and fuel cardiac metabolic remodeling 
by, for instance, impairing cardioprotective mechanisms 
downstream PKA and CREB or AMPK such as PGC1-
mediated transcription of genes related to fatty acid oxi-
dation or mitochondrial fusion. The increase in GRK2 
could also contribute to further impair cardiac insulin 
signaling decreasing the ability of cardiac cells to uptake 
glucose and making them less energetically efficient. This 
would result in inefficient cardiac ATP production with 
detrimental consequences for the heart [12, 13, 47]. In 
such scenario, GRK2 upregulation would be a relatively 
early event in the development of the metabolically-
induced cardiomyopathy, as has recently been suggested 
[47], and as is the case for other cardiac conditions in 
which GRK2 levels increase in the first stages of the heart 
disease [16].
In summary, our results point to a protective role 
of low levels of GRK2 upon obesity-induced cardiac 
remodeling and steatosis. The protection afforded by 
GRK2 downmodulation is apparent in the presence of 
concurrent relevant risk factors for insulin resistance 
and cardiovascular disease such as age and obesity after 
long-term HFD feeding. It is tempting to hypothesize 
that the increase in cardiac GRK2 protein levels triggered 
as a consequence of HFD feeding or in different patho-
physiological situations would play a central role allowing 
progression to maladaptive tissue and metabolic cardiac 
remodeling due to its unique ability to simultaneously 
alter GPCR and insulin signaling.
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